Friday, July 1, 2022
HomeMust ReadProstate Urine Risk Pur Test

Prostate Urine Risk Pur Test

Psa Test: The Current Prostate Screening Standard

The ExoDx Prostate test for Risk Assessment of high grade prostate cancer (HGPCa)

Before recommending when you should be screened for prostate cancer, yourdoctor will consider many factors, such as:

  • Age
  • Family history, particularly whether any of your family members have had prostate cancer
  • Race, as African-American men have a higher risk of developing prostate cancer

If your doctor determines you should undergo screening, he or she will mostlikely recommend the PSA test. For more than 30 years, the PSA test hasbeen the gold standard in prostate cancer screening. This simple blood testmeasures how much prostate-specific antigen is in your blood.

Prostate Cancer Diagnoses And Treatment

All cancer is complex, but prostate cancer testing and treatment is particularly complicated.

In some men with prostate cancer, the cancer will grow very slowly, and wont significantly affect them during their lifetime. Other mens prostate cancer can grow and spread very quickly. At the moment, there is no test that can tell what type of prostate cancer a man has when he is diagnosed.

Because some treatments for prostate cancer can cause side effects which might impact on quality of life, its important for men to discuss with their doctor all their options for testing and treatment, and to discuss these with their partners and families. These might include watchful waiting, which means waiting to see what the cancer does over time, radiation, surgery or taking medications.

You can read more about what kinds of questions to ask your doctors about prostate cancer testing and treatment on the Cancer Council website.

Improving Upon The Psa Test

The limited reliability of the PSA test, and its lack of specificity for prostate cancer, has led to sharp disagreement over the use of the PSA test as a routine health screening measure for men of a certain age. What everyone does agree upon is the need for better markers of prostate cancer. To date there are no perfect biomarkers that identify only high-risk prostate cancer. But each year progress is made toward such a goal. Today, the University of Michigans Department of Pathology MLabs will begin offering the MiPS urine test that is ultra specific for prostate cancer. The MiPS test scans urine samples for two molecular markers that are distinct to prostate cancer. One marker is a snippet of RNA made from a gene that is overactive in 95 percent of all prostate cancers. The second marker is RNA that is made only when two genes abnormally fuse. The presence of this fusion RNA in a mans urine is ultra specific for prostate cancer.

Don’t Miss: What Food Causes Enlarged Prostate

New Prostate Cancer Blood Test

If you have an abnormal PSA score, your doctor may recommend another newertest that gives a better sense of yourprostate cancer risk. The prostate health index is one such test that is a more accurateblood test and measures your risk for having prostate cancer. Its approvedby the FDA for men who have PSA scores between 4 and 10.

What are the benefits of the PHI test?

  • Fewer unnecessary biopsies: Some men who have elevated PSA scores are unsure about getting an invasive biopsy. This tool can be used to better determine whether your risk is high enough to warrant a biopsy.
  • More accurate: This test is better at detecting prostate cancer. It can also detect whether you have a more aggressive type of cancer. This information can guide doctors to a more targeted treatment plan for you.

If you score low on the PHI test, your doctor may recommend monitoring youover time to see if your levels rise enough to cause concern.

Urine Test Can Help Diagnose Aggressive Prostate Cancer

New Urine Test Can Diagnose Prostate Cancer Earlier ...

Recent research has revealed that a new urine test can detect aggressive prostate cancer cases that need treatment up to 5 years sooner than other diagnostic methods.

Researchers from the University of East Anglia in Norwich, United Kingdom, and the Norfolk and Norwich University Hospital carried out the study.

They revealed that an experimental urine test, called Prostate Urine Risk , can distinguish who will and who will not require treatment within the first 5 years of diagnosis.

The findings now appear in the journal BJU International.

Prostate Cancer News

Also Check: What Is The Latest Prostate Surgery Technique

Prostate Cancer Urine Test

This test detects the gene PCA3 in your urine and can also help your doctorbetter assess your prostate cancer risk.

PCA3 is a prostate-specific noncoding RNA. Its a gene thats only in yourprostate. If the gene is overexpressed , then theres a greater chance you have prostate cancer.

Like PSA and PHI tests, this isnt definitive, either. But data suggestthat when cancer is present, the PCA3 will be positive 80 percent of thetime. This test can also help your doctor determine whether a biopsy isnecessary.

Both of these new tests are more accurate than the PSA test. Your doctormay recommend one or more than one, based on the specifics of your case.

New Urine Test For Prostate Cancer Available Unlike Psa Test Is Ultra

September 25, 2013 A new urine test for prostate cancer that measures minute fragments of RNA is now commercially available to men nationwide through the University of Michigan MLabs. The new testMi-Prostate Score improves the utility of the PSA blood test, increases physicians ability to pick out high-risk prostate tumors from low-risk tumors in patients, and may help tens of thousands of men avoid unnecessary biopsies.

The MiPS test incorporates blood PSA levels and two molecular RNA markers specific for prostate cancer in one final score that provides men and their doctors with a personalized prostate-cancer risk assessment.

Don’t Miss: How To Fix A Swollen Prostate

Study: New Prostate Cancer Test Could Avoid Unnecessary Biopsies

Urine test found to be extremely accurate at detecting aggressive prostate cancer with few false negatives.

A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients. The findings appear in the March issue of the Journal of Urology.

The MyProstateScore test, which is being commercialized by LynxDX, a U-M startup company, measures levels of cancer-specific genes in a patients urine. It is based on U-M research that discovered that half of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG relocate on a chromosome and fuse together creating an on-switch for prostate cancer development.

Currently, one of doctors best methods for detecting prostate cancer is a blood test for prostate-specific antigen, commonly known as the PSA test. Elevated PSA levels may indicate cancer, but the majority of men with an elevated PSA do not actually have prostate cancer.

Our ultimate goal was to determine whether the MyProstateScore test could be a practical, reliable test that could rule out the need for more costly or invasive testing in men referred for a prostate biopsy, says study lead author Jeffrey Tosoian, M.D., M.P.H., a clinical lecturer in urology at Michigan Medicine.

Scientists Develop Home Urine Test Kit That Can Accurately Spot Prostate Cancer Risk

Getting Started with the ExoDx Prostate Test

The research team hopes that the introduction of the ‘At-Home Collection Kit’ could revolutionise diagnosis of the disease.

Scientists have developed a novel urine test kit that can help detect prostate cancer risk at home. The test diagnoses aggressive prostate cancer and predicts whether patients will require treatment up to five years earlier than standard clinical methods.

The ‘PUR’ test could be performed on samples collected at home, so men don’t have to come into the clinic to provide a urine sample or have to undergo an uncomfortable rectal examination, according to researchers from the University of East Anglia and the Norfolk and Norwich University Hospital.

This is an important step forward, because the first urination of the day provides biomarker levels from the prostate that are much higher and more consistent.

The research team hopes that the introduction of the ‘At-Home Collection Kit’ could revolutionise diagnosis of the disease.

“Prostate cancer usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men,” said lead researcher Dr Jeremy Clark from UEA’s Norwich Medical School.

The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination , an MRI scan or a biopsy.

Don’t Miss: What Is The Treatment For Prostate Cancer That Has Spread

Prostate Cancer: New Urine Test Hope

Health editor, BBC News online

An experimental new urine test can reveal if men with early prostate cancer will probably need aggressive therapy or can be left untreated but monitored, UK researchers say.

Current PSA blood tests cannot do this, meaning many men experience unnecessary worry, investigations and treatment.

The prostate urine risk test looks for genetic markers to give a more accurate assessment.

Trials in 537 patients suggest it can reliably sort men by risk.

It is one of a number of new tests – including other urine-based ones, as well as blood tests and scans – scientists are pursuing to improve prostate cancer detection.

A combination of checks rather than one single test may ultimately prove to be the best approach, experts say.

Prostate cancer is the most common cancer affecting men in the UK, with 47,000 new cases a year.

New Urine Test Shows Promising Results In Detecting Classifying Risk For Prostate Cancer

A newly published article in BJU International has described a way to test post-DRE urine samples for the presence of specific types of ribonucleic acid and use these data to detect and classify risk levels for more and less aggressive forms of prostate cancer.

The full text of this new article by Connell et al. is available on line, and is also discussed in a whole series of media articles .

It should be noted that the only other test that has ever been based on post-DRE urine samples never really met the promise that it seemed to hold. One question obviously relates to the vigorousness with which a DRE has to be carried out prior to collection of the urine sample. However,

The new test described by Connell et al. does seem to hold out cconsiderable promise if the data can be validated in prospective trials moving forward.

What we know at the present time is basically the following:

  • The research team set out to develop prostate urine risk signatures for four subsets of men:
  • Men with normal prostate tissue, and no evident risk for prostate cancer
  • Men with DAmico low-risk prostate cancer
  • Men with DAmico intermediate-risk prostate cancer
  • Men with DAmico high-risk prostate cancer
  • Urine samples from 535 men collected at multiple centers were used to create the PUR signatures.
  • The signatures were based on analysis of post-DRE urine samples for levels of urinederived extracellular vesicle RNA .
  • The researchers report the following core results:

    The authors conclude that:

    Read Also: Does Aspirin Help Enlarged Prostate

    New Prostate Cancer Urine Test Shows How Aggressive Disease Is And Could Reduce Invasive Biopsies

    Published by Communications

      Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is.

      A new study published today shows how an experimental new test called ExoGrail has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy.

      The research team say their new test could reduce the number of unnecessary prostate cancer biopsies by 35 per cent.

      Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a mans lifetime.

      The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination , an MRI scan or an invasive biopsy.

      However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men.

      Lead researcher Dr Dan Brewer, from UEAs Norwich Medical School and also a visiting worker at the Earlham Institute, said: While prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from.

      Invasive biopsies come at considerable economic, psychological and societal cost to patients and healthcare systems alike.

      The ExoGrail test also provided risk scores for patients and highlighted those for which an invasive biopsy would have been beneficial.

      New Prostate Cancer Urine Test Shows How Aggressive Disease Is

      Prostate Cancer Diagnosis with Urine Test

      Test could reduce invasive biopsies

      University of East Anglia

      New prostate cancer urine test shows how aggressive disease is and could reduce invasive biopsies

      Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is.

      A new study published today shows how an experimental new test called ‘ExoGrail’ has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy.

      The research team say their new test could reduce the number of unnecessary prostate cancer biopsies by 35 per cent.

      Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime.

      The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination , an MRI scan or an invasive biopsy.

      However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men.

      Lead researcher Dr Dan Brewer, from UEA’s Norwich Medical School, said: “While prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from.

      Invasive biopsies come at considerable economic, psychological and societal cost to patients and healthcare systems alike.”

      Journal

      Cancers

      Media Contact

      Read Also: What Does Low Grade Prostate Cancer Mean

      The Prostate Cancer Test

      Considering prostate cancers prevalence in society it is the most common cancer in men in the UK and with the knowledge of enhanced biomarker prevalence early in the day, Clark set out to develop a test that could effectively process samples collected at home, early in the morning, without the need for patients to travel to provide the sample.

      The resultant prostate urine risk test also circumvents the need for more invasive, time consuming and uncomfortable diagnostic methods for prostate cancer diagnosis, such as blood tests, biopsy, MRI and digital rectal examination .

      The PUR test measures gene expression in the urine samples, which can be posted to labs for analysis, and can provide key indicators of the malignancy of a tumor.

      Contents of the at-home collection kit. Invitation to participate. Study information sheet. Two urine collection tubes containing dried Norgen preservative. Two consent forms . Disposable non-allergenic glove. Pen . 1-h frog timer. Sealable plastic bag with wadding. Preaddressed postage-paid SafeBox for returning the samples.

      Pca3 Not Entirely Accurate

      However, the PCA3 urine test is not 100% accurate. There have been many reports of men with PCA3 scores of > 100 who have been found to be negative for prostate cancer after multiple biopsies, according to one author. Nonetheless, it still has value for patients who have already had one or more biopsies that did not find cancer. For them, several published studies support that the PCA3 test can help avoid an unnecessary repeat biopsy if it returns a score under 35.

      Not having to have a prostate biopsy is usually a relief. No one enjoys undergoing a transrectal ultrasound guided biopsy with its risks of pain, bleeding, and infection. Patients suspected of having prostate cancer, or those who have been treated but may be at risk for recurrence, all wish there were a simple liquid biopsy that did not involve sticking needles into the prostate gland but was accurate.

      Also Check: Where To Go For Prostate Exam

      Prostate Cancer: Advancements In Screenings

      Reviewed By:

      Dr. Christian Paul Pavlovich

      You may know thatprostate canceris one of the most common cancer types in men. The good news is that thereare many treatment and management options, even if the cancer is caught ata later stage.

      What you may not know: There are several options when it comes toprostate cancer screening. After considering multiple factors, your doctor may recommend theprostate-specific antigen test, and/or one of the newer screeningtests that are now available.

      Johns Hopkins urologistChristian Pavlovich, M.D., explains what you should know.

      Urine Test Could Help Prevent Cervical Cancer: Study

      Urine test shows prostate cancer risk

      “Prostate cancer usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men,” said lead researcher Dr Jeremy Clark from UEA’s Norwich Medical School.

      The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination , an MRI scan or a biopsy.

      We developed the PUR test, which looks at gene expression in urine samples and provides vital information about whether a cancer is aggressive or low risk.

      The research team provided 14 participants with an “At Home Collection Kit”, and instructions.

      They then compared the results of their home urine samples, taken first thing in the morning, with samples collected after a digital rectal examination.

      “We found that the urine samples taken at home showed the biomarkers for prostate cancer much more clearly than after a rectal examination. And feedback from the participants showed that the at home test was preferable,’ the authors wrote in a paper published in the journal BioTechniques.

      Because the prostate is constantly secreting, the collection of urine from men’s first urination of the day means that the biomarker levels from the prostate are much higher and more consistent, so this is a great improvement, they added.

      Recommended Reading: Effects Of Having Prostate Removed

      RELATED ARTICLES

      Most Popular